問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 1,704

    Total Beds

  • 806

    Total Doctors

  • ctc@ms.kmuh.org.tw
  • Yu-Sam Lin
  • 886-7-3121101#6643
  • 807Kaohsiung CityKaohsiung SanminNo.100, Tzyou 1st Rd., Sanmin Dist.,Sanmin,Kaohsiung City 807

Recruiting Trial

596Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1336Cases

2010-12-01 - 2017-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Study ended9Sites

2010-05-01 - 2014-07-31

Phase III

Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients with Alzheimer’s Disease.

  • Condition/Disease

    Alzheimer's disease

  • Test Drug

    Solanezumab

Participate Sites
6Sites

Terminated6Sites

2011-03-15 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2011-07-01 - 2013-12-31

Phase III

A prospective, randomized, double-blind trial comparing the long-acting basal insulin analogue LY2963016 and Lantus® in adult patients with type 2 diabetes

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    LY2963016

Participate Sites
8Sites

Terminated8Sites

2012-12-01 - 2016-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Study ended8Sites

2016-12-31 - 2023-12-31

Phase III

A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease

  • Condition/Disease

    Prodromal Alzheimer's Disease

  • Test Drug

    Solanezumab (LY2062430)

Participate Sites
10Sites

Terminated9Sites

2016-02-01 - 2018-06-17

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study

  • Condition/Disease

    Episodic Migraine

  • Test Drug

    LY2951742

Participate Sites
6Sites

Terminated6Sites

2014-12-01 - 2016-07-31

Phase III

Prospective, randomized, open, and comparative long-acting basal insulin analogue LY2963016 and LANTUS® (LANTUS®) in adults with type 2 diabetes: ELEMENT 5 trial.

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    LY2963016

Participate Sites
7Sites

Terminated7Sites

2023-07-03 - 2028-07-26

Phase III

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)

  • Condition/Disease

    Obesity 、Overweight、 Overweight or Obesity

  • Test Drug

    LY3502970

Participate Sites
5Sites

Recruiting5Sites

2023-04-01 - 2025-12-31

Phase I/II

A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

  • Condition/Disease

    Malignant Solid Tumor

  • Test Drug

    Gen1042

Participate Sites
7Sites

Recruiting7Sites

1 113 114 115 116 117 134
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB